Company: STAA
Filing Date: 2025-09-26
Form Type: DEFA14A
Source: 0001193125-25-219844
Chunk: 38

Company: STAAR SURGICAL CO
Filing Date: 2025-09-26
Form: DEFA14A
Chunk 38
---
 fees which, in the last seven years, had not                                                                                                    
 exceeded $90,000 per year. Further, she terminated her consulting arrangement with Alcon in October 2024 and has not received any consulting fees since November 2024                                                                 
 •Prior to the Board’s approval of the Alcon merger agreement, the Board determined that she did not have an interest in Alcon or                                                                                                      
 the potential transaction with Alcon that would impair her ability to exercise her independent business judgment in evaluating the potential transaction                                                                              |

| • |     | A claim that STAAR’s largest customer in China “has maintained a 10% overall growth target”                                                                                                                                                  
 is not a marker for future upside at STAAR. STAAR’s largest customer in China’s 10% overall growth target includes the full complement of refractive surgery options, including laser vision correction and ICL surgeries, among other       
 procedures. ICLs are only a portion of their overall refractive offering. This customer’s performance cannot be extrapolated to all STAAR customers in China and is not indicative of STAAR’s overall customer base in China. STAAR believes 
 China procedure volumes were positive year over year in 1Q 2025, softened during 2Q 2025, and have not improved so far in 3Q 2025.                                                                                                           |

The STAAR Board of Directors strongly recommends that all STAAR stockholders vote “FOR” the Alcon Merger on the WHITE proxy card TODAY.

Stockholders with questions about voting their shares should contact STAAR’s proxy solicitor, Innisfree M&A Incorporated:

| • |     | For stockholders: +1 877-750-8233 
 (toll-free)                       |

| • |     | For banks and brokerage firms: +1 
 212-750-5833                      |

About STAAR Surgical STAAR Surgical (NASDAQ: STAA) is the global leader in implantable phakic intraocular lenses, a vision correction solution that reduces or eliminates the need for glasses or contact lenses. Since 1982, STAAR has been dedicated solely to ophthalmic surgery, and for 30 years, STAAR has been designing, developing, manufacturing, and marketing advanced Implantable Collamer ®Lenses (ICLs), using its proprietary biocompatible Collamer material. STAAR ICL’s are clinically-proven to deliver safe long-term vision correction without removing corneal tissue or the eye’s natural crystalline lens. Its EVO ICL